TY - THES A1 - Reiser, Pia T1 - Das Adverse Outcome Pathway (AOP) – Konzept als Grundlage für die Entwicklung mechanistischer tierversuchsfreier Ansätze: Eine Fallstudie über Nephrotoxizität initiiert durch rezeptorvermittelte Endozytose und lysosomalen Overload T1 - The Adverse Outcome Pathway (AOP) concept as a framework for the development of mechanistic non-animal approaches: a case study of nephrotoxicity initiated by receptor-mediated endocytosis and lysosomal overload N2 - Zur Verbesserung der Prüfung und Risikobewertung der zunehmenden Menge von Chemikalien und Arzneimitteln, gilt es neue Alternativen in Form von in vitro Prüfmethoden mit mechanistisch relevanten Endpunkten zu finden. Einen solchen Rahmen bietet das konzeptionelle Konstrukt des Adverse Outcome Pathway (AOP)- Konzepts. Es erzeugt auf der Basis bestehenden Wissens einen mechanistischen und kausalen Zusammenhang mit Hilfe von mehreren Schlüsselereignissen (Key Event [KE]) zwischen einem initierenden molekularen Ereignis (Molecular Initiating Event [MIE]) und einem adversen Effekt (Adverse Outcome [AO]) auf biologischer Ebene. Im Rahmen dieser Arbeit wurde der AOP „Rezeptorvermittelte Endozytose und lysosomaler Overload führen zu Nephrotoxizität“ am Zellkulturmodell proximaler Nierentubuluszellen weiterentwickelt. Es wurden in vitro Assays für die Zelllinien RPTEC/TERT1 (Mensch) und NRK-52 E (Ratte) für jedes KE etabliert. In dem AOP wird die Initiierung der Schädigung des Nierengewebes durch rezeptorvermittelte Endozytose der Substanzen (MIE) mit folgendem lysosomalem Overload (KE 1) und der lysosomalen Membranruptur (KE 2) beschrieben. Es kommt zur Zellschädigung (KE 3) und endet mit einem Schaden auf Organebene (AO). Für KE 1 erfolgte die Visualisierung des lysosomal-assoziierten Membranproteins (lysosomal-associated Membranprotein [LAMP]) und in KE 2 die Darstellung der Protease Cathepsin D (CTSD) mittels Immunfluoreszenz. Für KE 3 wurden spezifische Toxizitätsdaten der Testsubstanzen mit dem CellTiter-Glo® Lumineszenz-Zellviabilitätstest generiert. Gewählte Stressoren für den AOP war die Gruppe der Polymyxin-Antibiotika (Polymyxin B, Colistin, Polymyxin B Nonapeptid), das Aminoglykosid Gentamicin, das Glykopeptid Vancomycin sowie Cadmiumchlorid. In Zusammenschau der Ergebnisse der drei KEs war die Rangfolge der Auswirkungen der drei Polymyxin-Derivate über alle KEs konsistent. Polymyxin B erwies sich als aktivste Substanz, während Polymyxin B Nonapeptid die geringsten Auswirkungen zeigte. Als Ausblick in weiterführenden Analysen der Arbeitsgruppe konnten bei Cadmiumchlorid trotz einer signifikanten Zytotoxizität (KE 3) nur geringe Auswirkungen in der LAMPExpression (KE 1) aufgezeigt werden. Des Weiteren erfolgte die Erstellung von Response-Response-Analysen, um mittels vorgeschalteter Schlüsselereignisse nachfolgende Effekte vorhersagen zu können. Projektpartner der Universität Utrecht entwickelten darüber hinaus eine quantitative in vitro in vivo Extrapolation (QIVIVE) mittels eines physiologisch basierten pharmakokinetischen (PBPK) Modells. N2 - To improve testing and risk assessment of the increasing amount of chemicals and drugs, new alternatives of in vitro testing methods with mechanistically relevant endpoints need to be found. The conceptual construct of the Adverse Outcome Pathway (AOP) concept provides such a framework. It generates a mechanistic and causal relationship based on existing knowledge using multiple key events (KE) between an initiating molecular event (MIE) and an adverse outcome (AO) at a biological level. In this work, the AOP "Receptor-mediated endocytosis and lysosomal overload lead to nephrotoxicity" was further developed using a cell culture model of proximal renal tubular cells. In vitro assays were established for the RPTEC/TERT1 (human) and NRK-52E (rat) cell lines for each KE. In the AOP, initiation of renal tissue damage by receptor-mediated endocytosis of substances (MIE) with subsequent lysosomal overload (KE 1) and lysosomal membrane rupture (KE 2) is described. Cell damage occurs (KE 3) and ends with organ damage (AO). For KE 1, visualization of lysosomal-associated membrane protein (LAMP), and for KE 2, visualization of protease cathepsin D (CTSD) was used by immunofluorescence. For KE 3, specific test substance toxicity data were generated using the CellTiter-Glo® luminescence cell viability assay. Selected stressors for the AOP were polymyxin antibiotics (polymyxin B, colistin, polymyxin B nonapeptide), the aminoglycoside gentamicin, the glycopeptide vancomycin, and cadmium chloride. All results of the three KEs combined, the ranking of the effects of the three polymyxin derivatives was consistent across all KEs. Polymyxin B proved to be the most active compound, while polymyxin B nonapeptide showed the lowest effects. In further analyses of the working group, only minor effects in LAMP expression (KE 1) could be shown with cadmium chloride despite a significant cytotoxicity (KE 3). Furthermore, response-response analyses were performed to predict upstream effects by downstream key events. Project partners from Utrecht University also developed a quantitative in vitro to in vivo extrapolation (QIVIVE) using a physiologically based pharmacokinetic (PBPK) model. KW - Nephrotoxizität KW - Lysosom KW - Endozytose KW - Adverse Outcome Pathway KW - rezeptorvermittelte Endozytose KW - lysosomaler Overload KW - tierversuchsfrei Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318046 ER - TY - JOUR A1 - Jarzina, Sebastian A1 - Di Fiore, Stefano A1 - Ellinger, Bernhard A1 - Reiser, Pia A1 - Frank, Sabrina A1 - Glaser, Markus A1 - Wu, Jiaqing A1 - Taverne, Femke J. A1 - Kramer, Nynke I. A1 - Mally, Angela T1 - Application of the adverse outcome pathway concept to in vitro nephrotoxicity assessment: kidney injury due to receptor-mediated endocytosis and lysosomal overload as a case study JF - Frontiers in Toxicology N2 - Application of adverse outcome pathways (AOP) and integration of quantitative in vitro to in vivo extrapolation (QIVIVE) may support the paradigm shift in toxicity testing to move from apical endpoints in test animals to more mechanism-based in vitro assays. Here, we developed an AOP of proximal tubule injury linking a molecular initiating event (MIE) to a cascade of key events (KEs) leading to lysosomal overload and ultimately to cell death. This AOP was used as a case study to adopt the AOP concept for systemic toxicity testing and risk assessment based on in vitro data. In this AOP, nephrotoxicity is thought to result from receptor-mediated endocytosis (MIE) of the chemical stressor, disturbance of lysosomal function (KE1), and lysosomal disruption (KE2) associated with release of reactive oxygen species and cytotoxic lysosomal enzymes that induce cell death (KE3). Based on this mechanistic framework, in vitro readouts reflecting each KE were identified. Utilizing polymyxin antibiotics as chemical stressors for this AOP, the dose-response for each in vitro endpoint was recorded in proximal tubule cells from rat (NRK-52E) and human (RPTEC/TERT1) in order to (1) experimentally support the sequence of key events (KEs), to (2) establish quantitative relationships between KEs as a basis for prediction of downstream KEs based on in vitro data reflecting early KEs and to (3) derive suitable in vitro points of departure for human risk assessment. Time-resolved analysis was used to support the temporal sequence of events within this AOP. Quantitative response-response relationships between KEs established from in vitro data on polymyxin B were successfully used to predict in vitro toxicity of other polymyxin derivatives. Finally, a physiologically based kinetic (PBK) model was utilized to transform in vitro effect concentrations to a human equivalent dose for polymyxin B. The predicted in vivo effective doses were in the range of therapeutic doses known to be associated with a risk for nephrotoxicity. Taken together, these data provide proof-of-concept for the feasibility of in vitro based risk assessment through integration of mechanistic endpoints and reverse toxicokinetic modelling. KW - adverse outcome pathway (AOP) KW - nephrotoxicity KW - QIVIVE KW - risk assessment KW - key event relationship KW - In vitro toxicity testing Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-284796 SN - 2673-3080 VL - 4 ER -